Last reviewed · How we verify
Atezolizumab, Etoposide, Carboplatin, Tarlatamab
Atezolizumab, Etoposide, Carboplatin, Tarlatamab is a PD-1/PD-L1 inhibitor Small molecule drug developed by Se-Hoon Lee. It is currently in Phase 2 development for Non-small cell lung cancer, Urothelial carcinoma, Triple-negative breast cancer.
PD-L1 inhibitor
PD-L1 inhibitor Used for Non-small cell lung cancer, Urothelial carcinoma, Triple-negative breast cancer.
At a glance
| Generic name | Atezolizumab, Etoposide, Carboplatin, Tarlatamab |
|---|---|
| Sponsor | Se-Hoon Lee |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Atezolizumab is a monoclonal antibody that binds to PD-L1, preventing its interaction with PD-1 and thereby enhancing T-cell mediated immune response against cancer cells.
Approved indications
- Non-small cell lung cancer
- Urothelial carcinoma
- Triple-negative breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (PHASE1)
- Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atezolizumab, Etoposide, Carboplatin, Tarlatamab CI brief — competitive landscape report
- Atezolizumab, Etoposide, Carboplatin, Tarlatamab updates RSS · CI watch RSS
- Se-Hoon Lee portfolio CI
Frequently asked questions about Atezolizumab, Etoposide, Carboplatin, Tarlatamab
What is Atezolizumab, Etoposide, Carboplatin, Tarlatamab?
How does Atezolizumab, Etoposide, Carboplatin, Tarlatamab work?
What is Atezolizumab, Etoposide, Carboplatin, Tarlatamab used for?
Who makes Atezolizumab, Etoposide, Carboplatin, Tarlatamab?
What drug class is Atezolizumab, Etoposide, Carboplatin, Tarlatamab in?
What development phase is Atezolizumab, Etoposide, Carboplatin, Tarlatamab in?
What are the side effects of Atezolizumab, Etoposide, Carboplatin, Tarlatamab?
What does Atezolizumab, Etoposide, Carboplatin, Tarlatamab target?
Related
- Drug class: All PD-1/PD-L1 inhibitor drugs
- Target: All drugs targeting PD-L1
- Manufacturer: Se-Hoon Lee — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Urothelial carcinoma
- Indication: Drugs for Triple-negative breast cancer
- Compare: Atezolizumab, Etoposide, Carboplatin, Tarlatamab vs similar drugs
- Pricing: Atezolizumab, Etoposide, Carboplatin, Tarlatamab cost, discount & access